Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

MK-7684A (new drug co-formulation of pembrolizumab with an anti-TIGIT) plus docetaxel works to help stop or slow down the growth of your non… Ended

2022-501252-28-00 Non Small Cell Lung cancer 4 2021-04-15
A Study to Evaluate Effects of RO7121661 and RO7247669 Compared With Nivolumab in Advanced or Metastatic Squamous Cell Carcinoma of the Esop… Ended

2024-511403-41-00 Advanced or metastatic squamous cell carcinoma of the e 4 2021-04-14
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab Ended

2024-515490-10-00 Multiple Myeloma 4 2021-04-12
A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific muta… Ended

2024-513060-26-00 Non-small cell lung cancer 7 2021-04-07
Isatuximab in combination with pegenzileukin in RRMM previously exposed to anti-CD38 and anti- BCMA Ended

2024-514990-23-00 Cancer 9 2021-03-31
Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations Ended

2024-511449-21-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 4 2021-03-25
A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended

2023-509513-36-00 Melanoma (Stage III and IV) 4 2021-03-24
Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended

2023-503291-24-00 Locally Advanced or Metastatic Solid Tumors, and Expans 9 2021-03-17
RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in pa… Ended

2024-513982-38-00 Metastatic or unresectable advanced rare sarcomas 5 2021-03-17
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P… Ended

2023-509449-10-00 Squamous cell carcinoma of the head and neck (SCCHN) 4 2021-03-16
A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors Ended

2024-513625-23-00 Patients with relapsed or refractory solid tumors, incl 1 2021-03-15
“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini… Ended

2023-508001-25-00 Metastatic Thymic Carcinoma & B3-thymoma. 4 2021-03-15
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended

2023-507086-26-00 Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse 7 2021-03-09
Study of Monalizumab Given With Cetuximab or Placebo Given with Cetuximab in Patients With Head and Neck Cancer that has come back or spread… Ended

2024-511813-39-00 Patients With Recurrent or Metastatic Squamous Cell Car 5 2021-03-04
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Ended

2024-518529-14-00 Metastatic/advanced soft tissue sarcoma (STS), Merkel c 7 2021-02-26
Phase I/II trial of S65487 plus azacitidine in acute myeloid leukemia Ended

2023-510051-27-00 Acute Myeloid Leukemia (AML) 7 2021-02-25
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga… Ended

2023-504834-23-00 Advanced/Metastatic Gastroesophageal Adenocarcinoma 11 2021-02-24
Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended

2023-504944-32-00 Non-clear Cell Renal Cell Carcinoma 4 2021-02-17
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Parti… Ended

2024-512687-66-00 non-Hodgkin lymphoma and chronic lymphocytic leukemia 3 2021-02-16
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and… Ended

2023-504403-92-00 Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) a 1 2021-02-15
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) Ended

2024-511140-37-00 OligoRecurrent prostate cancer 4 2021-02-12
A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors Ended

2024-515175-35-00 Locally Advanced or Metastatic Solid Tumors 1 2021-02-10
Safety and efficacy of adding immunotherapy combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (M… Ended

2024-514598-23-00 Limited metastatic pancreatic cancer 9 2021-02-09
A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations Ended

2024-516369-36-00 - Acute myeloid leukemia - Myelodysplastic syndrome/ My 3 2021-02-09